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Abstract
Postural instability and gait difficulty (PIGD) are commonly observed in advanced
Parkinson’s disease. The neuronal mechanism of PIGD is not fully understood.
Dysfunction of the pedunculopontine nucleus (PPN) might be a possible cause
of these symptoms. The autopsy studies of subjects with PIGD revealed
a neurodegenerative process involving mainly PPN cholinergic neurons. The PPN
participates in the locomotion processes by initiation, modulation and execution
of stereotyped patterns of movement. The standard neurosurgical treatment
of PD is subthalamic deep brain stimulation (STN DBS). Clinical results revealed
low efficiency of STN DBS on PIGD. Preliminary results of simultaneous PPN and
STN DBS are very promising. Only a few reports have been published until now;
a significant improvement of PIGD was observed in both ON and OFF L-dopa
states.
K Ke ey y   w wo or rd ds s: :   pedunculopontine nucleus, Parkinson’s disease, deep brain stimulation.
Introduction 
Parkinson’s disease (PD) is a neurodegenerative disorder, which affects
1-2% of the population above 60 years old. It is estimated that around 
5 million people worldwide [1] and 80 thousand in Poland suffer from PD
[2]. Postural instability and gait difficulty (PIGD) [3] are the cardinal motor
symptoms observed in 16% of PD patients [4]. Frequency of PIGD is higher
in old-age onset of PD [5]. Pharmacological treatment, including l-dopa,
frequently can cause significant side effects and becomes less effective
with PD progression. Symptoms such as PIGD, freezing and dysautonomia
are refractory to standard pharmacological treatment, which could be
explained by progressive degeneration of the non-dopaminergic system
in PD. Postural instability and gait difficulty are associated with the gait
initiation phase (GI), which consists of two elements: the preparation
period  and  a movement  execution  period  [6].  Gait  initiation  uses
stereotyped, coordinated patterns of limbs and trunk movements. Gait
initiation difficulties are caused by two factors: (1) prolongation of gait
preparation, execution interval and difficulty in recalling stereotyped,
adequate  motor  programme  sequences,  and  (2)  impaired  motor
programme selection and coordination of the movements involved. In
recent decades, the standard non-pharmacological treatment of PD has
become deep brain stimulation (DBS) [7]. Subthalamic nucleus (STN) DBS
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is  not  as  effective  in  PIGD  as  in  other  motor
symptoms. It is speculated that PIGD may result
from damage of non-dopaminergic systems, such
as the mesencephalic locomotor region (MLR).
Mesencephalic locomotor region is composed of
the  pedunculopontine  nucleus  (PPN)  and  the
cuneiform nucleus, which contain both cholinergic
and non-cholinergic neurons [8]. Pedunculopontine
nucleus dysfunction may be responsible for PIGD
in PD. It appears that PPN DBS is a promising new
target for PIGD. Recent clinical results confirm the
effectiveness of this therapeutic procedure [9]. 
The authors present a review of the literature on
the application of PPN DBS for the treatment of
PIGD in PD, including the anatomy and physiology
of the PPN and clinical results.
Anatomy of pedunculopontine nucleus
The PPN is located in the dorsolateral part of the
pontomesencephalic tegmentum, at the level of the
trochlear nucleus. It is delimited by the superior
cerebellar  peduncles  medially,  by  the  medial
lemniscus  laterally  and  ventrally  and  by  the
cuneiform nucleus dorsally. The PPN is separated
from the STN by the retrorubral field [10]. Histo  -
logically, the PPN is composed of two sub-regions:
the  pars  compacta  (cPPN)  and  pars  dissipata
(dPPN). The cPPN consists of a compact cluster of
large neurons, located within the caudal half of the
nucleus in its dorsolateral region. The dPPN is the
main part of the PPN and arises in the superior
cerebellar  peduncle  and  tegmental  tract,  with
uncertain boundaries [10]. There are around 10 000
to 15 000 cholinergic neurons within the PPN. Two
subgroups of cholinergic, choline-acetyltransferase
positive neurons have been identified. Most Ch5
neurons incorporate the PPN territory and Ch6 are
within the area corresponding to the lateral dorsal
tegmental nucleus [11]. Physiologically, three types
of cholinergic cells have been identified: 1) low
threshold spikes cells; 2) cells with a transient
outward current; 3) and cells with both charac  -
teristics [12]. There is a wide spectrum of receptor
heterogeneity in the PPN cholinergic system. Fifty
percent of the neurons express α2a and 30% αa1
receptors. Some of the cholinergic cells co-release
substance P, enkephalin, calbindin, calretinin and
parvalbumin. The non-cholinergic neurons belong
to the glutaminergic and GABAergic system [13]. 
Anatomical and electrophysiological studies have
revealed numerous putative connections with brain
structures including the cortex, limbic structures,
basal ganglia, thalamus, brainstem, cerebellum and
spinal cord (Figure 1). The PPN is closely functionally
related with the reticular activating system, by its
cholinergic and glutaminergic connections with
intralaminar thalamic nuclei resulting in global
activation  of  the  brain.  Chemical  or  electrical
stimulation  of  PPN  is  followed  by  prolonged
depolarization of thalamocortical cells and gamma
oscillations  in  EEG.  These  electrophysiological
changes are similar to those observed in wake  -
fulness and REM sleep [14]. Pedunculopontine
nucleus receives descending projections from the
ipsilateral prefrontal and motor cortex. The cortico-
tegmental tract, intermingled with the pyramidal
tract, descends to the level of the substantia nigra,
where they leave the cerebral peduncle and target
the PPN. Cortico-PPN connections are organized
somatotopically from medial to lateral (orofacial,
forelimb, hindlimb) [15]. Cortical afferents are mainly
glutaminergic. Limbic structures (amygdale, hip  -
pocampus and cingulated gyrus) send indirect
efferent  fibres  to  the  PPN  via  the  nucleus
accumbens, ventral tegmentum area and ventral
pallidum [16]. 
The most important and complex connections
of the PPN are those formed by reciprocal pathways
with basal ganglia, especially with the internal
globus pallidus (GPi) and substantia nigra (SN).
Globus pallidus and SN send the major afferents to
the PPN by GABAergic transmission. Pallidal fibres
descend  along  the  pallidotegmental  tract,
originating from the medial segment of the GPi and
terminating in the non-cholinergic cells of the dPPN
[17]. These inhibitory pathways efferent mainly to
the ipsilateral PPN, and only 10-20% pass to the
contralateral PPN. Over 80% of pallidal neurons
send collaterals to the ventrolateral nucleus of the
thalamus. Animal studies have revealed pedunculo  -
pallidal  fibres,  passing  along  both  the  ansa
lenticularis and lenticular fascilulus [18]. Both SNr
(substantia  nigra,  pars  reticulata)  and  SNc
(substantia nigra, pars compacta) send projections
to the PPN (Figure 2). These fibres divide into two
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branches,  one  nigro-tectal,  terminating  in  the
deeper layer of the superior colliculus, and the
second, the smaller part in the PPN [19, 20]. The
PPN  sends  direct  efferent,  glutaminergic  and
cholinergic connections to the SNc and indirect
connections  via  the  STN  to  the  SNr.  The  STN
innervates the PPN by direct connections ori  gi  -
nating in the lateral STN and indirect connections
by collaterals of STN-GP and STN-SN pathways 
[20, 21]. Numerous thalamic projections, especially
to the centrolateral, ventro  lateral and reticular
nucleus, pass through the PPN. The PPN-thalamic
pathways control thalamic activity and pass to the
striatum, as part of the subcor  tical-thalamus-basal
ganglia-subcortical loop [22, 23]. Other identified
PPN-striatum connections proceed through mid  -
brain dopaminergic neurons. Projec  tions for  ming
the anterior PPN region run to the SNc and those
from the posterior region terminate in the ventral
tegmental area. The colla  terals of PPN-thalamic
pathways are the main source of dopaminergic
innervations for midbrain neurons [24, 25]. There
are two main brainstem structures connected with
the  PPN:  brainstem  reticular  nuclei  (pontine
reticular nuclei oralis and caudal, ventromedial
portion  of  gigantocellular  nucleus)  and  peria  -
queductal grey matter [26]. The PPN projections to
the cerebellar fastigial nucleus, red nucleus and
spinal cord play an important role in the genesis of
axial symptoms in PD [27, 28]. 
A study with diffusion tensor imaging (DTI) [28]
in 8 volunteers found multiple neural connections
previously identified in animals. Pathways between
the PPN and primary motor cortex had features of
heterogeneity among the participants. Connections
with the upper extremity were present in 87.5% of
patients, the lower extremity in 62.5%, the trunk in
56.25%, and the orofacial region in only 12.5% of
patients. All these connections passed via the
posterior limb of the internal capsule. In 75% of
volunteers, pathways to the cerebellum via the
superior cerebellar peduncle were shown, com  pa  -
rably with monkey studies. In all cases connections
with the spinal cord were noted. Comparison of
human  and  monkey  (Macaca  mulatta)  PPN
connectivity determined using probabilistic diffusion
tractography (PDT) and histological tracing tech  -
niques revealed certain anatomical dissimilarities
[29].  Human  PPN  connections  with  SN  were
displayed in less than half of all subjects; the same
tracts are more prominent in monkeys. Other dif  -
ferences could be noted in the reciprocal functional
organization and representation of primary motor
cortex and PPN. This anatomical discrepancy may
reflect the human bipedal and standing posture and
quadrupedal gait in primates. 
Neuroimaging of gait with fMRI showed an
increased BOLD signal in MLR with the overall
reduction of BOLD activity in basal ganglia of PD
patients. Opposite effects were observed in the
control  group  [30].  Single  photon  emission
computed tomography with [99mTc]hexamethyl-
propyleneamine oxime during gait on a treadmill
revealed increased regional cerebral blood flow
(rCBF) in MLR. These findings were considered as
characteristic only for quadrupedal animals [31]. 
The PET study with 15-O-labelled CO demon  -
strated diminished regional cerebral blood flow of
the supplementary motor area associated with
hypokinesia in PD. These findings were observed
only  during  voluntary  movements;  no  rCBF
deviation appeared during triggered movements.
Hypothetically, distinct motion regulative systems
could be mediated by the connections from the
globus pallidus internus via the pedunculopontine
nucleus to the cerebellum [32].
Functional anatomy of pedunculopontine
nucleus
The PPN is part of the MLR, which is functionally
defined as the area of the brainstem responsible
for  locomotion.  The  outputs  of  the  MLR  are
bilaterally distributed to the reticulospinal cells in
the  ventromedial  medulla,  with  an  ipsilateral
predominance. The MLR descending projections
enable  coordination  of  limbs  and  postural
movements. The physiological analysis of PPN
function is mainly based on animal studies. The
human analysis with fMRI confirmed increased
Pedunculopontine nucleus deep brain stimulation in Parkinson’s disease
F Fi ig gu ur re e   2 2. .   Connection of PPN with basal ganglia
PPN – pedunculopontine nucleus, SNr – substantia nigra,
pars reticulata, SNc – substantia nigra, pars compacta, 
GPi – internal globus pallidus
Indirect connections
Direct connections
SNr
STN
GPi
Ventrolater
thalamus
PPN
SNc558 Arch Med Sci 4, August / 2011
Tomasz Tykocki, Tomasz Mandat, Paweł Nauman
activity of the left PPN in right-handed healthy
subjects during imaging of gait motion. However,
this study presents only the indirect evidence of
locomotor involvement of PPN, because obtaining
fMRI during gait motion is technically impossible
[33]. Electrical stimulation at 50-60 Hz near the PPN
in chronic pain patients revealed increased tone in
the contralateral limb muscles [34]. Three groups
of functional PPN cells were distinguished: 1) ‘on’
cells – with tonic firing activity on locomotion and
stopped entirely with the cessation of motion: 
2) ‘off’ cells – displaying a tonic firing pattern with
frequency  increase  before  motion  cessation; 
3) ‘bursters’ – displaying a bursting pattern of firing
on  locomotion.  The  on/off  cells  modulate  the
duration of locomotion, while the bursters control
the intensity and initiation of gait [35]. Unilateral
PPN kainic acid or radiofrequency lesions in the
animal  studies resulted  in  contralateral  hemi  -
parkinsonism [36]. 
The PPN cholinergic neurons are part of the
motivation and reward circuit and are combined 
with the limbic and brainstem motivational system.
The PPN receives inputs from limbic and striatum,
acting as a selective and coordinative centre for the
affective impulses, preparing a programmed motor
reaction, appropriate to the emotional status [37].
The PPN is afferently connected with the dorsolateral
ventral pallidum (dVP) and sends two projections: 
1) to the spinal cord through the brainstem motor
nuclei; 2) to the ventral tegmen  tum area, which
mediate dopaminergically to the nucleus accumbens
and dVP, which close the loop [38]. 
Post-stimulation (PPN DBS) DTI results showed
normalization of cortical and brainstem connectivity
in one analysed PIGD patient. Previously absent
cerebellar connectivity was now restored. The
abnormal,  anterior  pontine  connectivity  was
reduced and reorganized, so that the dominant
connectivity was with the pre-frontal cortical areas,
instead of the primary motor cortex [39]. Dis  -
crepancy of PPN connection in different subtypes
of PD patients was found. Imaging with DTI FA
detected absence of PPN connectivity to any part
of the cerebellum in PIGD patients, whereas the
non-PIGD  PD  group  displayed  significant  con  -
nectivity with the cerebellum, similar to, although
not completely overlapping with healthy normal
controls. The PIGD patients showed anterior pontine
connectivity at the level of the mid-section of the
fourth ventricle, which was absent in non-PIGD PD
patients and controls. These results support the
central  role  of  the  cerebellum  in  the  patho  -
mechanism  of  PIGD.  Increased  activity  of  the
anterior  pons  may  reflect  the  compensatory,
enhanced corticopontocerebellar projections in PIGD
patients [40]. 18-fluorodeoxyglucose (FDG)-positron
emission tomography (PET) of 6 PD patients during
PPT DBS showed significantly increased FDG uptake
in prefrontal and frontal bilateral cortical areas,
including  superior  and  inferior  frontal  gyri,
dorsolateral prefrontal and orbitofrontal cortex,
anterior  cingulated,  supramarginal  gyrus  and
inferior parietal lobule. Moreover, PPN DBS induced
increased FDG consumption in the left ventral
striatum, right insula and right superior temporal
gyrus. These findings stress the involvement of the
PPN not only in movement coordination, but some
participation in cognitive, emotional and executive
functions [41]. A [15O]H2O PET study showed that
unilateral PPN stimulation induced a significant
regional cerebral blood flow increase in subcortical
regions such as the cerebellum, thalamus bilaterally
and MLR. Additionally, PPN DBS during motor limb
movement resulted in increased rCBF in the medial
sensorimotor cortex extending into the caudal
supplementary  motor  area.  Presumably,  PPN
modulation  may  induce  functional  changes  in
neural networks associated with the control of
lower limb movements [42]. 
The rapid eye movement (REM) sleep state is
characterized by a desynchronized electro  encepha  -
logram. Physiologically, the REM mechanism is
a complex process, involving various neurotrans  -
mitters and coordination of the appropriate brain
structure. The mesopontine reticular activating
system (RAS), which modulates the sleep-wake
cycle, is composed of PPN, locus coeruleus and
raphe nucleus. All these three structures act in
functionally reciprocal connections. During the
waking state all these structures are active. The 
PPN cholinergic neurons decrease firing during
slow-wave sleep; they become active during wake
and REM state, that is in fast cortical rhythms [43]. 
The PPN is also a part of primary acoustic startle
reactions. A single acoustic stimulus activates the
ventral cochlear nucleus and PPN, which send
cholinergic  inhibitory  signals  to  the  nucleus
reticularis pontis caudalis. The PPN modulates and
regulates the sensorimotor gating information from
the forebrain [44].
Neuropathology of pedunculopontine nucleus
The PIGD may reflect the loss of neurons and
dysfunction of the PPN in PD patients. However,
there  are  no  data  explaining  whether  the
neurodegenerative processes of SN and PPN are of
the same kind. Some authors report that 40-50%
of cholinergic neurons degenerate in PD. Lewy
bodies  were  observed  in  remaining  PPN  cells,
indicating primary neurodegeneration [45]. The loss
of catecholaminergic cells has also been deter  -
mined. The decrease of cholinergic cells may result
in overactivity of intact glutaminergic neurons [46],
which innervate the dopaminergic SNc region. 
This effect accelerates or even causes the nigralArch Med Sci 4, August / 2011 559
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degeneration. Pallidal-nigral projections are mainly
inhibitory and in consequence lead to expanded
PPN  inhibition  [47].  Therefore,  there  are  two
possible  mechanisms  of  PPN  insufficiency,
neurodegeneration and functional inhibition. There
is no correlation between PD duration and extent
of PPN neuronal loss; also, intact PPN structures in
PD brains were found [45]. That is in contradiction
to  animal  models,  which  revealed  that  MPTP
treatment induced 30% more expanded loss of
cholinergic neurons in aged subjects, in comparison
with young ones [33]. 
Karachi et al. [33] analysed post mortem brain
sections of three groups: 1) PD patients without
balance deficit and falls (non-faller, nfPD); 2) PD
patients with balance deficits and falls (faller, fPD);
3) healthy controls. The number of cholinergic cells
in fPD patients was significantly lower than in nfPD
and controls. The loss of dopaminergic neurons was
also more extensive in fPD than in nfPD. There was
no difference in the number of cuneiform nucleus
cells in both PD groups, which indicates that PPN
impairment rather than the extent of degeneration
is the cause of PIGD. Bilateral lesions of PPN in
animal models resulted in significant changes in
gait  and  posture  at  7-8  weeks  follow-up.  No
changes of global motor activity was observed and
the symptoms did not improve after application of
apomorphine [33]. Simultaneous PPN local field
potentials and cortical EEG showed a correlation
between motor cortex activity and PPN. Dopa  -
minergic  medications  modulate  PPN  synchro  -
nization with voluntary movements and the ON
state promotes cortical-PPN interactions [48]. A PET
study in nfPD and fPD patients showed significantly
lower  cholinergic  activity  in  the  fPD  group.
Cholinergic dysfunction seems to be crucial for PIGD
and  is  a possible  target  for  pharma  cological
intervention. Administration of scopola  mine, an
antimuscarinic agent, has been reported to worsen
gait in progressive supranuclear palsy (PSP) and
elderly  patients  [49,  50].  There  is  preliminary
evidence that varenicline selective α4β2, a nicotinic
receptor agonist, may have a beneficial effect on
gait;  promising  results  have  been  reported  in
patients with ataxia [51]. Studies have also shown
a positive association between PIGD in PD and
increased  risk  of  dementia  [52,  53].  However, 
there are no studies investigating and answering
whether the cholinergic pathology of PIGD and PD
dementia are of the same kind. 
Pedunculopontine nucleus deep brain
stimulation
Ablative techniques and deep brain stimulation
are recommended for surgical treatment of PD.
Neuromodulation with DBS includes such targets
as the STN, nucleus ventralis intermedius thalami
(Vim) and globus pallidus pars interna (GPi). It is
believed that STN DBS produces the widest effect
on  motor  symptoms  in  PD.  Nevertheless,  the
benefits in PIGD after STN DBS are no so promoting
and tend to decline with the natural course of the
disease. Previous animal studies and pioneer clinical
trials of low frequency PPN DBS showed significant
amelioration of gait and postural deficits in PD.
Jenkinson et al. [54] reported the effects of unilateral
PPN stimulation in macaques before and after
inducing parkinsonism with MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine). Stimulation at
frequency 5 Hz showed increased motor activity in
MPTP monkeys comparable to that observed after
levodopa treatment. Similar results were noted in
normal macaques. Another animal study with the
6-hydroxydopamine (6-OHDA) rat model inves  -
tigated the reciprocal interactions in basal ganglia
circuits.  In  6-OHDA  rats  the  STN  and  SNr  are
hyperactive  and  after  unilateral  ibotenic  acid
lesioning of PPN the activity of both the STN and
SNr returned to the baseline [55]. However, Rauch
et al. [56] in a detailed analysis of PPN stimulation
in a 6-OHDA rat model reported a non-uniform
response to high and low frequencies according to
different  motor  functions:  locomotor  activity,
postural instability and limb use. These complex
responses  to  PPN  stimulation  require  further
investigations. A trial with microinjection of bicu  -
culline, a GABA A antagonist, into the PPN of
parkinsonian monkeys clearly proved alleviation of
akinesia [57].
The first clinical reports of benefits with PPN DBS
come from 2005, when Mazzone et al. [58] and
Plaha et al. [59] published their results (Table I).
Bilateral PPN DBS alone, without previous STN DBS
or simultaneous implantation or stimulation of STN,
revealed  improvement  in  the  total  Unified
Parkinson's Disease Rating Scale (UPDRS) – 53%
and UPDRS part III (motor subscore) – 57% and
levodopa reduction of 32.5%. The two selected
patients had dominant symptoms of PIGD and
freezing. Postoperative follow-up was performed at
day 42 for the first patient and day 16 for the
second  one.  The  best  clinical  response  was
observed at frequencies between 20 Hz and 25 Hz
[59]. Electrophysiological recordings directly from
the PPN during synchronous stimulation of STN
produced only slight changes in PPN firing activity,
while the same stimulation provoked increased SNr
activity. These findings demonstrate that the STN-
PPN pathway in humans is not so extensive as is
observed in rodents and cats [58]. Stefani et al. [60]
proposed simultaneous bilateral implantation of
DBS electrodes in STN and PPN. PD patients with
PIGD  dominancy  were  included  with  UPDRS
(Unified Parkinson’s Disease Rating Scale) part III
score over 70. In OFF medication state the following560 Arch Med Sci 4, August / 2011
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reduction of UPDRS III was reported: 33% PPN DBS,
54% STN DBS, 56% STN plus PPN DBS. Including
only the axial signs (points 27-30 of UPDRS III), PPN
DBS was more effective than STN DBS alone but
less  than  STN  plus  PPN  DBS.  No  significant
differences among the three DBS conditions were
detected. The combination of L-dopa treatment
with DBS produced a significant reduction of the
UPDRS score (PPN DBS 72.4%, STN DBS 75.8%, PPN
and STN DBS 83.5%) in comparison with any OFF
medication  stimulation  or  with  L-dopa  alone
(50.2%).  The  PIGD  improvement  after  PPN
stimulation in the ON medication state seems to
be unusual, considering that axial symptoms are
generally ascribed to ‘non-dopaminergic’ dege  -
neration. Ferraye et al. [61] presented results of PPN
DBS  for  PIGD  with  a double-blind,  cross-over
stimulation study. Six patients were recruited with
refractory PIGD and previous STN DBS. Results were
ambiguous:  while  some  patients  significantly
improved after PPN DBS, others obtained moderate
benefits and one even worsened within one year
after the operation. Regarding the whole group,
freezing improved ON stimulation in comparison
with  OFF  stimulation,  in  both  OFF  and  ON
medication states. Outcomes in the Beck Depression
Inventory  and  mobility  subscale  of  PDQ-39
(Parkinson’s disease questionnaire) ameliorated
after  surgery,  but  did  not  achieve  statistical
significance. The PIGD did not respond to the
stimulation. Therefore, these observations could be
provoked by combined stimulation of cholinergic
and  glutaminergic  PPNc  and  PPNd  cells,  and
indirectly facilitating the dopaminergic striatal
system. Intraoperative recordings showed that PPN
DBS (25 Hz, 60 µs) affects the STN firing rate. Two
conflicting STN neuronal responses were observed
after PPN DBS: decreased firing in bursting neurons
and an excitatory effect in large tonic neurons.
Silence in burst neurons is in accord with a PPN
therapeutic effect, but increased tonic mode is not
desired [62]. Stimulation at frequency of 180 Hz
resulted in motor deterioration. PPN DBS modulates
descending basal ganglia-brainstem pathways. The
PD patients present an increased Hoffman reflex
(HR) threshold; this abnormality was significantly
reduced by DBS. In particular, it was found that
PPN-DBS alone, or plus STN-DBS, induced complete
normalization of the HR threshold [63]. The PPN-
DBS may act on spinal cord excitability by improving
the reticulospinal pathway transmission; thus the
effectiveness of the stimulation might be due not
only to the modulation of the basal ganglia circuits,
but also excitation of the pontomedullary reticular
formation  and  reticulospinal  nuclei  improving
descending spinal pathways. The PET imaging in
PD patients with unilateral PPN DBS revealed
increased regional blood flow in the thalamus,
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cerebellum, midbrain region and cortical areas
involving the medial sensorimotor cortex extending
into the caudal supplementary motor area [64]. The
PPN-DBS significantly improved executive functions
and  working  memory  and  reduced  sleep
fragmentation and comfort. This effect is probably
due to activation of cholinergic muscarin receptor
transmission from the PPN to the thalamus. 
Prospects for the future
Deep brain stimulation was introduced in the
1990s. Since then, DBS has become the standard
therapy in the treatment of movement disorders.
Neuromodulatory procedures for the treatment of
PD  appeared  to  be  clinically  effective,  as  they
decrease  the  severity  of  dominant  symptoms.
Nevertheless there is currently no evidence that DBS
inhibits the progression of the neuro  degenerative
process. In the course of PD, apart from the cardinal
motor  signs,  dysautonomia  and  psychiatric
symptoms are also distinguished. In the treatment
of these so-called non-motor symptoms, DBS seems
to be ineffective. Besides, there is also a group of
patients  who  do  not  respond  to  the  neuro  -
modulatory treatment for motor disturbances, in
particular those with severe axial symptoms such as
PIGD. Thus, investigations have been started to find
new potential anatomical and physiological targets
to increase the effectiveness of DBS in PD. One of
the  promising  targets  is  the  PPN,  and  the
simultaneous stimulation of the PPN and STN proved
effective in the treatment of PIGD. Further exploration
of an appropriate strategy in the neuromodulatory
therapy,  considering  the  selection  of  single  or
combined targets depending on the dominance of
symptoms in PD, may potentiate the effectiveness
of DBS. Great expectations are associated with other
therapeutic approaches, such as stem cells [65] or
gene  therapy  [66]  in  the  treatment  of  PD.
Transplantation of embryonic dopamine neurons for
severe PD seemed to be clinically very effective.
However, promising initial motor results were related
to serious graft-induced dyskinesias [67]. Further
investigation elucidated that the possible cause of
these side effects is the impact of grafted serotonin
neurons,  as  the  serotonin  neurons  lack  the
autoregulatory  feedback  control  typical  for
dopaminergic cells. In PD the physiological dopamine
transmission in the striatum is possibly replaced by
serotonin  neurons,  resulting  in  uncontrolled
dopamine release. Animal studies demonstrate that
graft-induced dyskinesias are evoked by high content
of serotonin neurons in the graft. However, at least
10-20% of non-degenerative dopaminergic striatal
neurons  are  sufficient  to  protect  against  the
dyskinesias  generated  by  new  serotoninergic
innervations. Therefore, human studies with respect
to the aforementioned results are needed [68]. 
Gene therapy is a new concept for alleviation of
symptoms and alteration of the progression of the
disease. A double-blind, randomized study with glial
cell line-derived neurotrophic factor (GDNF) via an
adeno-associated type-2 vector did not confirm
a significant  advantage  for  gene  therapy  in
comparison with other methods in the early follow-
up [69]. A previous animal and human open-label
trial [70] showed significant improvement in motor
scales with no serious side effects. Considering the
multiple degenerative brain process in PD, multi-
targeted GDNF delivery could be the solution for
better clinical outcomes. However, the authors
emphasize that in the longer observation gene
therapy may be more effective. 
High-resolution  brain  imaging  using  7.0 T
magnets could dramatically improve the accuracy
of the target visualization and provide detailed
information about the topography of the desired
anatomical area [71]. Ultra high-field MRI scanning
together  with  intraoperative  real-time  neuro  -
chemical  monitoring  and  neurophysiological
recordings may optimize not only the anatomical
targeting but also greatly improve the functional
navigation.  The  development  of  the  Wireless
Instantaneous Neurotransmitter Concentration
System (WINCS) [72] for neurochemical monitoring,
which  can  interface  with  carbon-fibre  micro  -
electrodes  or  enzyme-based  microsensors  to
measure extracellular concentrations of neuro  -
transmitters and neuromodulators. Fast-scan cyclic
voltammetry (FSCV) generates a voltammogram,
which is sent to a remotely located station where
the data are analysed and chemical identification
takes place. Real-time neurochemical monitoring
of the targeted regions may provide a new strategy
for investigation of DBS mechanisms and che  -
mically navigated placement of the stimulating
electrode. Another innovation, closed-loop respon  -
siveness stimulation, is an alternative for intelligent,
symptom-related stimulation [73]. This pattern of
DBS  has  already  been  introduced  in  epilepsy
treatment. The system is based on the feedback-
guided adjustment of stimulation calibrated with
neurophysiological and neurochemical monitoring
from the targeted area, for example PPN. Upon the
detection of abnormalities on monitoring, res  -
ponsive electrical stimulation is delivered. 
Future therapeutic options could be based on an
individual strategy taking into account combined
or single therapy considering pharmacotherapy,
neuromodulation or gene therapy.
Rationale for the application 
of pedunculopontine deep brain stimulation
The PPN was proposed as a new stereotactic
target for the neurosurgical treatment of PD. There
have been published only a few reports evaluating562 Arch Med Sci 4, August / 2011
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clinical results of PPN DBS in approximately 30
patients so far. The main reason supporting this
therapeutic approach is the significant impro  -
vement of axial symptoms in PD, in particular
freezing of gait, frequency of gait and postural
instability. Hitherto prevailing targets such as the
STN or GPi used for DBS tellingly ameliorated the
cardinal motor parkinsonian symptoms, but were
inefficient in the treatment of axial problems.
However, application of PPN DBS alone proved to
be less effective than STN DBS or GPi DBS for non-
axial symptoms, but simultaneous stimulation of
PPN and STN brought the best results for the
treatment of PIGD. Since the disability associated
with PIGD significantly affects the quality of life,
PPN  DBS  offers  a new  prospect  to  improve
comfort of PD patients. Also noteworthy is the
improvement  of  cognitive,  emotional  and
executive functions after PPN DBS. Additionally,
a decrease  in  awakenings  and  a significant
increase  in  REM  sleep  were  observed  after
stimulation. Simultaneous bilateral PPN and STN
DBS entails the need for implantation of eight
electrodes, which increase the risk of surgical
complications.  Therefore,  only  selected  PD
candidates with PIGD diagnosed by a neurologist
with experience in movement disorders should be
qualified for PPN DBS. To date, only outcomes of
pilot  studies  have  been  reported,  and  larger,
double-bind design series are necessary to confirm
these first promising results. 
Conclusions
The PIGD belong to the dopamine-resistant
symptoms. Although the effectiveness of STN DBS
for cardinal motor symptoms is well documented,
PIGD treatment is still unsolved. The PPN was
discovered as a central structure responsible for
coordination  of  locomotor  functions.  The  PPN
controls basal ganglia circuits and descending
brainstem  pathways.  According  to  the  animal
models and the complex mechanism of action, the
PPN was identified as a target for DBS in PIGD
treatment. The performance of combined STN and
PPN DBS treatment has shown its efficacy. The two-
target stimulation seemed more effective than the
stimulation of each target alone. The unsatisfactory
results  of  PPN  DBS  as  a single  target  for  PD
symptoms suggest that it can be explored only as
an additional target. The PPN DBS increased the
efficiency of both STN DBS and pharmacological
therapy used alone. The slight decline of PPN DBS
efficacy in PIGD over months raises the possibility
of adaptive changes, but longer follow-up is needed
to confirm this observation. The fundamental issue
is appropriate selection of patients for STN plus PPN
DBS. PPN DBS is dedicated to PD patients with
PIGD. 
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